Showing 1791-1800 of 3223 results for "".
- Alkeus Secures Rare Pediatric Disease and Fast Track FDA Designations for Gildeuretinol in Stargardt Diseasehttps://modernod.com/news/alkeus-secures-rare-pediatric-disease-and-fast-track-fda-designations-for-gildeuretinol-in-stargardt-disease/2482549/Alkeus Pharmaceuticals announced that its investigational oral therapy, gildeuretinol (ALK-001), has been granted Rare Pediatric Disease and Fast Track designations by the FDA for the treatment of Stargardt disease. “Stargardt disease imposes a relentless burden, robbing chil
- FDA Accepts Aldeyra's NDA for Reproxalap in Dry Eye Disease; Expands Partnership with AbbViehttps://modernod.com/news/fda-accepts-aldeyras-nda-for-reproxalap-in-dry-eye-disease/2482547/Aldeyra Therapeutics announced that the FDA has officially accepted for review the resubmitted new drug application (NDA) for its topical ocular therapy, reproxalap, aimed at treating the signs and symptoms of dry eye disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) target d
- MediPrint Ophthalmics Unveils Phase 2b Trial Results for Drug-Eluting Contact Lens in Glaucoma Treatmenthttps://modernod.com/news/mediprint-ophthalmics-unveils-phase-2b-trial-results-for-drug-eluting-contact-lens-in-glaucoma-treatment/2482539/MediPrint Ophthalmics announced positive results from its phase 2b clinical trial of its 3D-printed, drug-eluting contact lens LL-BMT1. The results, presented by Ian Ben Gaddie, OD, FAAO, at the Ameri
- Alcon Unveils PRECISION7 1-Week Contact Lens with ACTIV-FLO Technologyhttps://modernod.com/news/alcon-unveils-precision7-one-week-contact-lens-with-activ-flo-technology/2482533/Alcon announced the US launch of PRECISION7, the first contact lens designed for a 1-week replacement cycle. Leveraging the 7-day ACTIV-FLO system, these lenses are designed to deliver up to 16 hours of exceptional comfort and clear vision, even on the seventh day of wear. [1]
- AlloVir and Kalaris Announce Merger to Create Company Focused on Retina Diseasehttps://modernod.com/news/allovir-and-kalaris-therapeutics-announce-agreement-for-transformational-merger-to-create-company-focused-on-diseases-of-the-retina/2482532/AlloVir announced that it has entered into a definitive merger agreement to combine with Kalaris Therapeutics in an all-stock transaction. "On behalf of the AlloVir board, I am thrilled that we have entered into this transformational merger agreement with Kalaris,”
- Tarsus Appoints Elizabeth Yeu, MD, as Chief Medical Officerhttps://modernod.com/news/tarsus-appoints-elizabeth-yeu-md-as-chief-medical-officer/2482527/Tarsus Pharmaceuticals announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus’ chief medical advisor s
- Study of Alkeus' Oral Gildeuretinol Demonstrate Trend in Slowing GA Progression and Visual Function Improvementhttps://modernod.com/news/study-of-alkeus-oral-gildeuretinol-demonstrate-significant-trend-in-slowing-ga-progression-and-visual-function-improvement/2482511/Alkeus Pharmaceuticals announced findings from its SAGA study, which evaluated the investigational oral therapy gildeuretinol (ALK-001) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study showed a statistically significant reduction in GA l
- Alcon Collaborates with Eye Care Professionals to Identify and Address Unmet Needs in the Contact Lens Industryhttps://modernod.com/news/alcon-collaborates-with-eye-care-professionals-to-identify-and-address-unmet-needs-in-the-contact-lens-industry/2482485/A new Alcon program aims to identify and address current gaps in contact lens offerings by partnering with eye care professionals. With the new Alcon Innovator Program, 20 ‘innovators’ were selected to receive and offer their patients exclusive access to Alcon’s upcoming product
- Marinomed Biotech Reports Promising Phase 2 Results for Tacrosolv Eye Drops in Treating Allergic Rhinoconjunctivitishttps://modernod.com/news/marinomed-biotech-reports-promising-phase-2-results-for-tacrosolv-eye-drops-in-treating-allergic-rhinoconjunctivitis/2482473/Marinomed Biotech has announced clinical data from its phase 2 dose-finding clinical trial on Tacrosolv, a novel eye drop formulation for treating allergic rhinoconjunctivitis. The results, now published in the peer-reviewed journal Clinical Ophthalmology, indicate that Tacrosolv, formulated usin
- Aldeyra Resubmits NDA for Topical Ocular Reproxalap for Dry Eye Diseasehttps://modernod.com/news/aldeyra-resubmits-nda-for-topical-ocular-reproxalap-for-dry-eye-disease/2482469/Aldeyra Therapeutics announced the resubmission of a new drug application (NDA) to the FDA for its investigational topical drug, reproxalap, which is intended to treat the signs and symptoms of dry eye disease. The resubmission follows a recent FDA-requested trial that demonst